In HCC, PART1 has been shown to promote HCC progression by targeting the miR-590-3p/HMGB2 [17], miR-149-5p/MAP2K1 [18], and miR-3529-3p/FOXC2 axis [16]. This evidence concerns the gene MAP2K1 and hepatocellular carcinoma.